Nigeria Health Watch
Follow us:
breadcrumb banner

Lassa Fever

Categories

Blog Image 21 Nov

Are we there yet? Leveraging the Private Sector for Lassa Vaccine R&D

By Nigeria Health Watch | November 21, 2023

The search for an effective vaccine against Lassa fever has gained momentum in recent years. Currently, early supportive care and the anti-viral drug Ribavirin are the primary methods of patient treatment. Lassa fever has long been a public health concern in Nigeria and parts of West Africa, since the disease was first identified in 1969. […]

Read More
Blog Image 13 Jul

CEPI: Accelerating Lassa Fever Vaccine Development in Nigeria

By Nigeria Health Watch | July 13, 2023

The law of inertia, referred to as Newton’s first law of motion, states that “an object will remain at rest or in uniform motion in a straight line unless compelled to change its state by the action of an external force”. This is similar to the Coalition for Epidemic Preparedness Innovation’s (CEPI) mission to accelerate […]

Read More
Blog Image 4 Jul

Institute of Lassa Fever Research and Control: Strengthening Nigeria’s Local Capacity to Lead the Lassa Fever Response

By Nigeria Health Watch | July 4, 2022

By Beti Baiye and Ibukun Oguntola The driveway in the grounds of the Irrua Specialist Teaching Hospital (ISTH) is large and welcoming and as you enter the hospital premises, the hospital’s motto: ‘Patient is Supreme’ catches the eye. The hospital was founded in 1993 to manage viral haemorrhagic fever including Lassa fever and over the […]

Read More
Blog Image 22 Jan

When a Virus ‘Outstays its Welcome’: Lassa Virus found in the Semen of Survivors 9 Months after Recovery – implications for public health management

By Nigeria Health Watch | January 22, 2022

Editor’s Note: In this commentary Professor Sylvanus. A. Okogbenin, the Chief Medical Director of Irrua Specialist Teaching Hospital, discusses the significance of a new ground breaking study just published by his team in the pre-eminent medical journal, The Lancet, in which they describe the persistence of the virus in patients after recovery from acute Lassa […]

Read More
Blog Image 15 Jun

EDCTP and CEPI funding moves IAVI’s Lassa fever vaccine candidate into advanced clinical development

By Nigeria Health Watch | June 15, 2021

Global consortium of expert partners will generate proof-of-concept data to support product licensure and future access NEW YORK, THE HAGUE, AND OSLO – JUNE 15, 2021 – IAVI has received an award of €22.8 million from the European & Developing Countries Clinical Trials Partnership (EDCTP) and the Coalition for Epidemic Preparedness Innovations (CEPI) to conduct […]

Read More